NMPA Accepts New Drug Application for IBI301, a Biosimilar Product Candidate of Rituximab (MabThera/Rituxan)
SUZHOU, China, June 27, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801) and Eli Lilly and Company ("Lilly") jointly announced today that the National Medical Products Administration (NMPA) has accepted its new drug application (NDA) for IBI301, a co-developed biosimilar pro...
Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at 2019 ASCO and EHA Annual Meetings
SUZHOU, China, June 18, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the clinical results of CT103A, the potential best-in-class therapy of fully-human ...
Innovent provides Update on the Results of Sintilimab for the Treatment of Extranodal NK/T Cell Lymphoma by Oral Presentation at ASCO
SUZHOU, China, June 5, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the research data on the treatment of relapsed or refractory extranodal NK/T cell ly...
Innovent Provides Updates on Extended Follow-up on Sintilimab for Relapsed/Refractory Classical Hodgkin's Lymphoma
SUZHOU, China, June 4, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the results of extended follow-up on sintilimab, the anti-PD-1 antibody that co-deve...
Innovent Provides Update on Sintilimab in Combination with CAPOX for First-Line Treatment of Patients with Gastric or Gastroesophageal Junction Carcinoma (GC/GEJC)
SUZHOU, China, June 4, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the preliminary results of efficacy and safety of sintilimab, the anti-PD-1 antibody...
Updated Results on Neoadjuvant PD-1 Blockade with Sintilimab in Resectable Squamous Non-Small Cell Lung Cancer (sqNSCLC) at ASCO, Led by Professor Jie He, Dean of the Cancer Hospital of the Chinese Academy of Medical Sciences
SUZHOU, China, June 3, 2019 /PRNewswire/ -- The preliminary results of efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable squamous non-small cell lung cancer (sqNSCLC) (ChiCTR-OIC-17013726), led by ProfessorJie He, Dean of the Cancer Hospital of the Chinese Academy of ...
Innovent Provides Key Results Update of IBI305 (Biosimilar Product Candidate of Bevacizumab) Compared with Bevacizumab
SUZHOU, China, June 3, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the study results for efficacy and safety of IBI305 (biosimilar of bevacizumab) comp...
Innovent Provides Update on Phase Ib Study of Sintilimab in Combination with Chemotherapy for First-line Advanced or Metastatic Non-small Cell Lung Cancer
SUZHOU, China, May 31, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the preliminary results of sintilimab, the anti-PD-1 antibody that co-developed with...
Innovent Will Provide Key Results Update of Several Clinical Studies at 2019 ASCO Annual Meeting
SUZHOU, China, May 16, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the research data on the treatment of relapsed or refractory extranodal NK/T cell ly...
Two Clinical Studies with IBI301, a Biosimilar Candidate to Rituximab, Met Primary Endpoints
SUZHOU, China, May 8, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801) and Eli Lilly and Company ("Lilly") jointly announced today that IBI301, a recombinant human-mouse chimeric anti-cell surface protein (anti-CD20) monoclonal antibody being co-developed as a potential bios...
Innovent Announces First Patient Dosed in Phase I Clinical Trial of IBI318 Bispecific Antibody in China
SUZHOU, China, April 24, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the first patient inChina has been successfully dosed in a Phase I clinical trial ...
Innovent Announces First Patient Dosed in a Phase I Clinical Trial of IBI302 for the Treatment of Wet AMD
SUZHOU, China, April 18, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the first patient has been successfully dosed in a Phase I clinical trial of IBI30...
Innovent Receives 10th Anniversary CHIC IPO of the Year Award
SHANGHAI, March 28, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that it has received the 10th Anniversary China Healthcare Investment Conference (CHIC) "IPO...
Innovent Announces First Patient Dosed in a Phase IIa Clinical Study of IBI306, an Anti-PCSK9 Monoclonal Antibody
SUZHOU, China, March 21, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the first patient has been successfully dosed in a Phase IIa clinical study of IBI...
Innovent Announces First Patient Dosed in a Phase IIa Clinical Study of IBI306, an Anti-PCSK9 Monoclonal Antibody
SUZHOU, China, March 20, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the first patient has been successfully dosed in a Phase IIa clinical study of IBI...
Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-CD47 Monoclonal Antibody in the U.S.
SUZHOU, China, March 19, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the first patient has been successfully dosed in a Phase I clinical trial of anti-...
Innovent Announces 2018 Annual Results
HONG KONG, March 14, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced its audited annual results for the year ended31 December 2018. "2018 was a landmark year f...
First Patient Dosed in a Clinical Trial of Tyvyt® (Sintilimab injection) in Combination with IBI305 as First Line Treatment for Patients with Advanced Hepatocellular Carcinoma
SUZHOU, China, Feb. 28, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801) today announced that the first patient has been dosed in ORIENT-32, a trial that evaluates Tyvyt® (generic name: sintilimab injection), a fully human anti-programmed cell death protein 1 (anti-PD-1) mo...
Innovent Receives IFR Asia-Pacific IPO of the Year 2018 and IFR Asia Review Hong Kong Equity Issue of the Year 2018 Awards
HONG KONG, Feb. 27, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)
(HKEX: 01801), today announced that it received the International Finance
Review (IFR) Asia-Pacific IPO of the Year 2018 and IFR Asia Review Hong Kong
Equity Issue of the Year 2018 awards.
Innovent Organized a Forum Discussing the Pending Launch of its Anti PD-1 Tyvyt® (Sintilimab injection) as Part of the National Mega Innovation Program in Beijing
BEIJING, Feb. 22, 2019 /PRNewswire/ -- The Forum for the National Mega Innovation Program in conjunction with the press conference on the launch of Tyvyt® (fully human anti-PD-1 therapeutic monoclonal antibody, generic name: sintilimab injection), hosted by Innovent Biologics, Inc. (Innovent) (HK...